Talecris Biotherapeutics, Inc. received approval from the FDA for Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a debilitating neurological disorder that results in muscle weakness and fatigue and can cause severe impairment of motor skills. Gamunex is the first therapy approved for the treatment of CIDP as well as the first IVIG therapy approved in the U.S. to treat a neur...